Neurofibromatosis: New Clinical Challenges in the Era of COVID-19
Rare diseases constitute a wide range of disorders thus defined for their low prevalence. However, taken together, rare diseases impact a considerable percentage of the world population, thus representing a public healthcare problem. In particular, neurofibromatoses are autosomal-dominant genetic di...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-04-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/10/5/940 |
| _version_ | 1797501433146245120 |
|---|---|
| author | Alessio Ardizzone Anna Paola Capra Michela Campolo Alessia Filippone Emanuela Esposito Silvana Briuglia |
| author_facet | Alessio Ardizzone Anna Paola Capra Michela Campolo Alessia Filippone Emanuela Esposito Silvana Briuglia |
| author_sort | Alessio Ardizzone |
| collection | DOAJ |
| description | Rare diseases constitute a wide range of disorders thus defined for their low prevalence. However, taken together, rare diseases impact a considerable percentage of the world population, thus representing a public healthcare problem. In particular, neurofibromatoses are autosomal-dominant genetic disorders that include type 1 neurofibromatosis (NF1), type 2 neurofibromatosis (NF2) and schwannomatosis. Each of the three types is a genetically distinct disease with an unpredictable clinical course and for which there is still no resolutive cure. Therefore, a personalized therapeutic approach directed at improving the symptomatology as well as the search for new pharmacological strategies for the management of neurofibromatosis represents a priority for positive outcomes for affected patients. The coronavirus disease 2019 (COVID-19) pandemic has severely affected health systems around the world, impacting the provision of medical care and modifying clinical surveillance along with scientific research procedures. COVID-19 significantly worsened exchanges between healthcare personnel and neurofibromatosis patients, precluding continuous clinical monitoring in specialized clinic centers. In this new scenario, our article presents, for the first time, a comprehensive literature review on the clinical challenges for neurofibromatosis clinical care and research during the COVID-19 pandemic health emergency. The review was performed through PubMed (Medline) and Google Scholar databases until December 2021. |
| first_indexed | 2024-03-10T03:18:20Z |
| format | Article |
| id | doaj.art-4d95d97461e04d3cad81a7aee8c963e2 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-10T03:18:20Z |
| publishDate | 2022-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-4d95d97461e04d3cad81a7aee8c963e22023-11-23T10:08:45ZengMDPI AGBiomedicines2227-90592022-04-0110594010.3390/biomedicines10050940Neurofibromatosis: New Clinical Challenges in the Era of COVID-19Alessio Ardizzone0Anna Paola Capra1Michela Campolo2Alessia Filippone3Emanuela Esposito4Silvana Briuglia5Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’Alcontres 31, 98166 Messina, ItalyDepartment of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’Alcontres 31, 98166 Messina, ItalyDepartment of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’Alcontres 31, 98166 Messina, ItalyDepartment of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’Alcontres 31, 98166 Messina, ItalyDepartment of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’Alcontres 31, 98166 Messina, ItalyDepartment of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, Via Consolare Valeria 1, 98125 Messina, ItalyRare diseases constitute a wide range of disorders thus defined for their low prevalence. However, taken together, rare diseases impact a considerable percentage of the world population, thus representing a public healthcare problem. In particular, neurofibromatoses are autosomal-dominant genetic disorders that include type 1 neurofibromatosis (NF1), type 2 neurofibromatosis (NF2) and schwannomatosis. Each of the three types is a genetically distinct disease with an unpredictable clinical course and for which there is still no resolutive cure. Therefore, a personalized therapeutic approach directed at improving the symptomatology as well as the search for new pharmacological strategies for the management of neurofibromatosis represents a priority for positive outcomes for affected patients. The coronavirus disease 2019 (COVID-19) pandemic has severely affected health systems around the world, impacting the provision of medical care and modifying clinical surveillance along with scientific research procedures. COVID-19 significantly worsened exchanges between healthcare personnel and neurofibromatosis patients, precluding continuous clinical monitoring in specialized clinic centers. In this new scenario, our article presents, for the first time, a comprehensive literature review on the clinical challenges for neurofibromatosis clinical care and research during the COVID-19 pandemic health emergency. The review was performed through PubMed (Medline) and Google Scholar databases until December 2021.https://www.mdpi.com/2227-9059/10/5/940rare diseasesneurofibromatosisCOVID-19clinical carepersonalized medicinepharmacogenetics |
| spellingShingle | Alessio Ardizzone Anna Paola Capra Michela Campolo Alessia Filippone Emanuela Esposito Silvana Briuglia Neurofibromatosis: New Clinical Challenges in the Era of COVID-19 Biomedicines rare diseases neurofibromatosis COVID-19 clinical care personalized medicine pharmacogenetics |
| title | Neurofibromatosis: New Clinical Challenges in the Era of COVID-19 |
| title_full | Neurofibromatosis: New Clinical Challenges in the Era of COVID-19 |
| title_fullStr | Neurofibromatosis: New Clinical Challenges in the Era of COVID-19 |
| title_full_unstemmed | Neurofibromatosis: New Clinical Challenges in the Era of COVID-19 |
| title_short | Neurofibromatosis: New Clinical Challenges in the Era of COVID-19 |
| title_sort | neurofibromatosis new clinical challenges in the era of covid 19 |
| topic | rare diseases neurofibromatosis COVID-19 clinical care personalized medicine pharmacogenetics |
| url | https://www.mdpi.com/2227-9059/10/5/940 |
| work_keys_str_mv | AT alessioardizzone neurofibromatosisnewclinicalchallengesintheeraofcovid19 AT annapaolacapra neurofibromatosisnewclinicalchallengesintheeraofcovid19 AT michelacampolo neurofibromatosisnewclinicalchallengesintheeraofcovid19 AT alessiafilippone neurofibromatosisnewclinicalchallengesintheeraofcovid19 AT emanuelaesposito neurofibromatosisnewclinicalchallengesintheeraofcovid19 AT silvanabriuglia neurofibromatosisnewclinicalchallengesintheeraofcovid19 |